Analysis of Off-Tumor Toxicities of T Cell-Engaging Bispecific Antibodies via Donor-Matched Intestinal Organoids and Tumoroids

Investigators showed that patient-derived intestinal organoids and tumouroids supplemented with immune cells could be used to study the on-target off-tumour toxicities of T cell-engaging bispecific antibodies (TCBs), and to capture clinical toxicities not predicted by conventional tissue-based models as well as inter-patient variabilities in TCB responses.